Serum β 2-microglobulin in the hemophilia AIDS and hepatitis C combined with highly active antiretroviral therapy to determine the role of.docVIP

 PAGE \* MERGEFORMAT 13 Serum β 2-microglobulin in the hemophilia AIDS and hepatitis C combined with highly active antiretroviral therapy to determine the role of [Abstract] Objective To investigate the serum β 2-microglobulin (serum β 2-MG) in the AIDS highly active antiretroviral therapy (HAART) to determine the role of efficacy. Methods combined hemophilia and hepatitis C in patients with AIDS receiving HAART 1 year 25 cases. Pre-treatment and treatment 1,3,6,9,12 months after the start of the first CD4 cell count at the end of testing, HIV-RNA load and serum β 2-MG. Treatment before and after the matching data analysis and related analysis. The results of treatment 1,3,6,9,12 months compared with pre-treatment CD4 cell count had increased significantly, HIV-RNA load compared with pre-treatment decreased significantly. 3,9,12 months of treatment, serum β 2-MG compared with pre-treatment also decreased significantly. Serum β 2-MG and the CD4 cell count, serum β 2-MG and HIV-RNA load of no good correlation between the. In serum β 2-MG in the HAART efficacy judgments have some monitoring role. [Keywords:] serum β 2-MG; CD4 cell count; HIV-RNA load; HAART The role of serum β 2-microglobulin in monitoring the efficiency of HAART in 25 AIDS patients [Abstract] Objective To know the role of serum β 2-microglobulin (serumβ 2-MG) in monitoring the efficiency of high active anti-retroviral therapy (HAART) in AIDS patients.Methods 25 AIDS patients with HCV () were treated with HAART for 1 year and their serumβ 2-MG, CD4 cell counts and HIV-RNA were measured before initiation of treatment and at the 1st, 3rd, 6th, 9th and12th month of treatment.The data was analyzed with pared-samples test and correlation test.Results CD4 cell counts were significantly increased and HIV-RNA decreased at the 1st, 3rd, 6th, 9th and12th month of treatment while serum β 2-MG were significantly decreased at the 3rd, 9th and12th month of treatment.Serum β 2-MG do not have correlatio